IL-17 in the immunopathogenesis of spondyloarthritis

被引:0
|
作者
Leonie S. Taams
Kathryn J. A. Steel
Ushani Srenathan
Lachrissa A. Burns
Bruce W. Kirkham
机构
[1] King’s College London,Centre for Inflammation Biology and Cancer Immunology (CIBCI), Department of Inflammation Biology, School of Immunology & Microbial Sciences
[2] Guy’s and St Thomas’ NHS Foundation Trust,Department of Rheumatology
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Spondyloarthritis (SpA) is a term that refers to a group of inflammatory diseases that includes psoriatic arthritis, axial SpA and nonradiographic axial SpA, reactive arthritis, enteropathic arthritis and undifferentiated SpA. The disease subtypes share clinical and immunological features, including joint inflammation (peripheral and axial skeleton); skin, gut and eye manifestations; and the absence of diagnostic autoantibodies (seronegative). The diseases also share genetic factors. The aetiology of SpA is still the subject of research by many groups worldwide. Evidence from genetic, experimental and clinical studies has accumulated to indicate a clear role for the IL-17 pathway in the pathogenesis of SpA. The IL-17 family consists of IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F, of which IL-17A is the best studied. IL-17A is a pro-inflammatory cytokine that also has the capacity to promote angiogenesis and osteoclastogenesis. Of the six family members, IL-17A has the strongest homology with IL-17F. In this Review, we discuss how IL-17A and IL-17F and their cellular sources might contribute to the immunopathology of SpA.
引用
收藏
页码:453 / 466
页数:13
相关论文
共 50 条
  • [1] IL-17 in the immunopathogenesis of spondyloarthritis
    Taams, Leonie S.
    Steel, Kathryn J. A.
    Srenathan, Ushani
    Burns, Lachrissa A.
    Kirkham, Bruce W.
    NATURE REVIEWS RHEUMATOLOGY, 2018, 14 (08) : 453 - 466
  • [2] IL-17 Inhibition in Axial Spondyloarthritis
    Danve A.
    Deodhar A.
    Current Treatment Options in Rheumatology, 2015, 1 (2) : 221 - 230
  • [3] Th17 cells and IL-17 A-Focus on immunopathogenesis and immunotherapeutics
    van den Berg, Wim B.
    McInnes, Iain B.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2013, 43 (02) : 158 - 170
  • [4] IL-17 in spondyloarthritis: is the T-party over?
    Nataliya Yeremenko
    Dominique Baeten
    Arthritis Research & Therapy, 13
  • [5] IL-17 inhibitors in axial spondyloarthritis. An overview
    Toussirot, Eric
    Felten, Renaud
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (09) : 917 - 932
  • [6] IL-17 in spondyloarthritis: is the T-party over?
    Yeremenko, Nataliya
    Baeten, Dominique
    ARTHRITIS RESEARCH & THERAPY, 2011, 13 (03)
  • [7] Effects of the IL-23–IL-17 pathway on bone in spondyloarthritis
    Ellen M. Gravallese
    Georg Schett
    Nature Reviews Rheumatology, 2018, 14 : 631 - 640
  • [8] The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis
    Tsukazaki, Hiroyuki
    Kaito, Takashi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (17) : 1 - 19
  • [9] The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases
    Berry, S. P. Deo-Gracias
    Dossou, Camille
    Kashif, Ali
    Sharifinejad, Niusha
    Azizi, Gholamreza
    Hamedifar, Haleh
    Sabzvari, Araz
    Zian, Zeineb
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 102
  • [10] Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers
    Groen, Solveig Skovlund
    Sinkeviciute, Dovile
    Bay-Jensen, Anne-Christine
    Thudium, Christian S.
    Karsdal, Morten A.
    Thomsen, Simon Francis
    Schett, Georg
    Nielsen, Signe Holm
    AUTOIMMUNITY REVIEWS, 2021, 20 (03)